Analysts Set Smith & Nephew plc (LON:SN) Price Target at GBX 1,346.20

Smith & Nephew plc (LON:SNGet Free Report) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is GBX 1,346.20 ($17.19).

A number of equities research analysts have recently commented on SN shares. Berenberg Bank restated a “buy” rating and set a GBX 1,450 ($18.52) target price on shares of Smith & Nephew in a research report on Thursday, May 2nd. Royal Bank of Canada restated an “outperform” rating and issued a GBX 1,500 ($19.16) price objective on shares of Smith & Nephew in a report on Tuesday, May 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 1,250 ($15.96) target price on shares of Smith & Nephew in a report on Friday, May 3rd. Barclays reissued an “equal weight” rating and issued a GBX 1,150 ($14.69) price target on shares of Smith & Nephew in a research note on Friday, February 9th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Smith & Nephew from GBX 1,300 ($16.60) to GBX 1,381 ($17.64) and gave the stock an “overweight” rating in a research report on Thursday, May 2nd.

Check Out Our Latest Stock Report on Smith & Nephew

Smith & Nephew Stock Performance

SN opened at GBX 987.40 ($12.61) on Tuesday. The firm’s 50-day moving average price is GBX 991.29 and its 200-day moving average price is GBX 1,042.62. The company has a market cap of ¬£8.63 billion, a P/E ratio of 4,084.17, a price-to-earnings-growth ratio of 0.49 and a beta of 0.51. Smith & Nephew has a 52-week low of GBX 887 ($11.33) and a 52-week high of GBX 1,269 ($16.21). The company has a quick ratio of 0.84, a current ratio of 1.77 and a debt-to-equity ratio of 59.11.

Smith & Nephew Company Profile

(Get Free Report

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

Read More

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.